Keeping Bio-Tech and Life Science Companies Healthy and Growing
We serve dozens of bio-tech and life sciences companies from their founding as early-stage, high-potential startups through maturity and sometimes, to their exit and liquidity event. Tax and accounting issues change rapidly in this industry segment, and mistakes and errors in tax compliance and/or financial reporting can have devastating consequences. Keiter partners with your company to keep you up to date on accounting changes within the industry and works with you to ensure you reach your companies business and financial goals.
Industry Focus
Bio-Techs and other high potential life sciences companies face complex tax and accounting issues among which are:
- Choosing between corporate or pass-through entity structure
- Debt and equity structure involving convertible debt and preferred interests and the associated GAAP and tax reporting issues
- SBIR and STTR grant reporting
- A-133 audits
- Governmental grant and contract accounting/reporting
- GAAP and tax reporting for compensatory equity interests
- Revenue recognition under licensing agreements and milestone contracts
- Liquidation events and exit strategies
- Federal research and experimentation credits
- Tax basis startup expenses and costs of raising capital
- §83(b) elections for equity incentive programs
- §§743 and 704(b) considerations for successive equity investments with differing valuations
- §1202 gain exclusion on Qualified Small Business Stock
- State tax incentives and credits
- Performing Internal audits, internal controls reviews, IT audits, and regulatory compliance reviews
Articles
Audit Requirements for Commercial Enterprises Receiving STTR/SBIR Grants (PDF) August 2011
